The global rheumatoid arthritis drugs market size is accounted at USD 64.35 billion in 2025 and is forecasted to hit around USD 75.53 billion by 2034, representing a CAGR of 1.80% from 2025 to 2034. The North America market size was estimated at USD 37.30 billion in 2024 and is expanding at a CAGR of 1.82% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
Rheumatoid Arthritis Drugs Market
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Rheumatoid Arthritis Drugs Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Rheumatoid Arthritis Drugs Market, by Drug Type
8.1.1. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
8.1.1.1. Market Revenue and Forecast
8.1.2. Corticosteroids
8.1.2.1. Market Revenue and Forecast
8.1.3. Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
8.1.3.1. Market Revenue and Forecast
9.1. Rheumatoid Arthritis Drugs Market, by Route of Administration
9.1.1. Oral
9.1.1.1. Market Revenue and Forecast
9.1.2. Parenteral
9.1.2.1. Market Revenue and Forecast
10.1. Rheumatoid Arthritis Drugs Market, by Distribution Channel
10.1.1. Hospital Pharmacies
10.1.1.1. Market Revenue and Forecast
10.1.2. Retail Pharmacies
10.1.2.1. Market Revenue and Forecast
10.1.3. Online Pharmacies
10.1.3.1. Market Revenue and Forecast
11.1. Rheumatoid Arthritis Drugs Market, by Patient Type
11.1.1. Adult
11.1.1.1. Market Revenue and Forecast
11.1.2. Paediatric
11.1.2.1. Market Revenue and Forecast
12.1. Rheumatoid Arthritis Drugs Market, by Mode of Purchase
12.1.1. Prescription-based
12.1.1.1. Market Revenue and Forecast
12.1.2. Over the counter
12.1.2.1. Market Revenue and Forecast
13.1. North America
13.1.1. Market Revenue and Forecast, by Drug Type
13.1.2. Market Revenue and Forecast, by Route of Administration
13.1.3. Market Revenue and Forecast, by Distribution Channel
13.1.4. Market Revenue and Forecast, by Patient Type
13.1.5. Market Revenue and Forecast, by Mode of Purchase
13.1.6. U.S.
13.1.6.1. Market Revenue and Forecast, by Drug Type
13.1.6.2. Market Revenue and Forecast, by Route of Administration
13.1.6.3. Market Revenue and Forecast, by Distribution Channel
13.1.6.4. Market Revenue and Forecast, by Patient Type
13.1.6.5. Market Revenue and Forecast, by Mode of Purchase
13.1.7. Rest of North America
13.1.7.1. Market Revenue and Forecast, by Drug Type
13.1.7.2. Market Revenue and Forecast, by Route of Administration
13.1.7.3. Market Revenue and Forecast, by Distribution Channel
13.1.7.4. Market Revenue and Forecast, by Patient Type
13.1.7.5. Market Revenue and Forecast, by Mode of Purchase
13.2. Europe
13.2.1. Market Revenue and Forecast, by Drug Type
13.2.2. Market Revenue and Forecast, by Route of Administration
13.2.3. Market Revenue and Forecast, by Distribution Channel
13.2.4. Market Revenue and Forecast, by Patient Type
13.2.5. Market Revenue and Forecast, by Mode of Purchase
13.2.6. UK
13.2.6.1. Market Revenue and Forecast, by Drug Type
13.2.6.2. Market Revenue and Forecast, by Route of Administration
13.2.6.3. Market Revenue and Forecast, by Distribution Channel
13.2.7. Market Revenue and Forecast, by Patient Type
13.2.8. Market Revenue and Forecast, by Mode of Purchase
13.2.9. Germany
13.2.9.1. Market Revenue and Forecast, by Drug Type
13.2.9.2. Market Revenue and Forecast, by Route of Administration
13.2.9.3. Market Revenue and Forecast, by Distribution Channel
13.2.10. Market Revenue and Forecast, by Patient Type
13.2.11. Market Revenue and Forecast, by Mode of Purchase
13.2.12. France
13.2.12.1. Market Revenue and Forecast, by Drug Type
13.2.12.2. Market Revenue and Forecast, by Route of Administration
13.2.12.3. Market Revenue and Forecast, by Distribution Channel
13.2.12.4. Market Revenue and Forecast, by Patient Type
13.2.13. Market Revenue and Forecast, by Mode of Purchase
13.2.14. Rest of Europe
13.2.14.1. Market Revenue and Forecast, by Drug Type
13.2.14.2. Market Revenue and Forecast, by Route of Administration
13.2.14.3. Market Revenue and Forecast, by Distribution Channel
13.2.14.4. Market Revenue and Forecast, by Patient Type
13.2.15. Market Revenue and Forecast, by Mode of Purchase
13.3. APAC
13.3.1. Market Revenue and Forecast, by Drug Type
13.3.2. Market Revenue and Forecast, by Route of Administration
13.3.3. Market Revenue and Forecast, by Distribution Channel
13.3.4. Market Revenue and Forecast, by Patient Type
13.3.5. Market Revenue and Forecast, by Mode of Purchase
13.3.6. India
13.3.6.1. Market Revenue and Forecast, by Drug Type
13.3.6.2. Market Revenue and Forecast, by Route of Administration
13.3.6.3. Market Revenue and Forecast, by Distribution Channel
13.3.6.4. Market Revenue and Forecast, by Patient Type
13.3.7. Market Revenue and Forecast, by Mode of Purchase
13.3.8. China
13.3.8.1. Market Revenue and Forecast, by Drug Type
13.3.8.2. Market Revenue and Forecast, by Route of Administration
13.3.8.3. Market Revenue and Forecast, by Distribution Channel
13.3.8.4. Market Revenue and Forecast, by Patient Type
13.3.9. Market Revenue and Forecast, by Mode of Purchase
13.3.10. Japan
13.3.10.1. Market Revenue and Forecast, by Drug Type
13.3.10.2. Market Revenue and Forecast, by Route of Administration
13.3.10.3. Market Revenue and Forecast, by Distribution Channel
13.3.10.4. Market Revenue and Forecast, by Patient Type
13.3.10.5. Market Revenue and Forecast, by Mode of Purchase
13.3.11. Rest of APAC
13.3.11.1. Market Revenue and Forecast, by Drug Type
13.3.11.2. Market Revenue and Forecast, by Route of Administration
13.3.11.3. Market Revenue and Forecast, by Distribution Channel
13.3.11.4. Market Revenue and Forecast, by Patient Type
13.3.11.5. Market Revenue and Forecast, by Mode of Purchase
13.4. MEA
13.4.1. Market Revenue and Forecast, by Drug Type
13.4.2. Market Revenue and Forecast, by Route of Administration
13.4.3. Market Revenue and Forecast, by Distribution Channel
13.4.4. Market Revenue and Forecast, by Patient Type
13.4.5. Market Revenue and Forecast, by Mode of Purchase
13.4.6. GCC
13.4.6.1. Market Revenue and Forecast, by Drug Type
13.4.6.2. Market Revenue and Forecast, by Route of Administration
13.4.6.3. Market Revenue and Forecast, by Distribution Channel
13.4.6.4. Market Revenue and Forecast, by Patient Type
13.4.7. Market Revenue and Forecast, by Mode of Purchase
13.4.8. North Africa
13.4.8.1. Market Revenue and Forecast, by Drug Type
13.4.8.2. Market Revenue and Forecast, by Route of Administration
13.4.8.3. Market Revenue and Forecast, by Distribution Channel
13.4.8.4. Market Revenue and Forecast, by Patient Type
13.4.9. Market Revenue and Forecast, by Mode of Purchase
13.4.10. South Africa
13.4.10.1. Market Revenue and Forecast, by Drug Type
13.4.10.2. Market Revenue and Forecast, by Route of Administration
13.4.10.3. Market Revenue and Forecast, by Distribution Channel
13.4.10.4. Market Revenue and Forecast, by Patient Type
13.4.10.5. Market Revenue and Forecast, by Mode of Purchase
13.4.11. Rest of MEA
13.4.11.1. Market Revenue and Forecast, by Drug Type
13.4.11.2. Market Revenue and Forecast, by Route of Administration
13.4.11.3. Market Revenue and Forecast, by Distribution Channel
13.4.11.4. Market Revenue and Forecast, by Patient Type
13.4.11.5. Market Revenue and Forecast, by Mode of Purchase
13.5. Latin America
13.5.1. Market Revenue and Forecast, by Drug Type
13.5.2. Market Revenue and Forecast, by Route of Administration
13.5.3. Market Revenue and Forecast, by Distribution Channel
13.5.4. Market Revenue and Forecast, by Patient Type
13.5.5. Market Revenue and Forecast, by Mode of Purchase
13.5.6. Brazil
13.5.6.1. Market Revenue and Forecast, by Drug Type
13.5.6.2. Market Revenue and Forecast, by Route of Administration
13.5.6.3. Market Revenue and Forecast, by Distribution Channel
13.5.6.4. Market Revenue and Forecast, by Patient Type
13.5.7. Market Revenue and Forecast, by Mode of Purchase
13.5.8. Rest of LATAM
13.5.8.1. Market Revenue and Forecast, by Drug Type
13.5.8.2. Market Revenue and Forecast, by Route of Administration
13.5.8.3. Market Revenue and Forecast, by Distribution Channel
13.5.8.4. Market Revenue and Forecast, by Patient Type
13.5.8.5. Market Revenue and Forecast, by Mode of Purchase
14.1. AbbVie
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. Boehringer Ingelheim GmbH
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. Novartis AG
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. Regeneron Pharmaceuticals, Inc.
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. Pfizer, Inc.
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. Bristol-Myers Squibb Company
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. F. Hoffmann-La Roche Ltd.
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. UCB S.A.
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
14.9. Johnson & Johnson Services, Inc.
14.9.1. Company Overview
14.9.2. Product Offerings
14.9.3. Financial Performance
14.9.4. Recent Initiatives
14.10. Amgen, Inc.
14.10.1. Company Overview
14.10.2. Product Offerings
14.10.3. Financial Performance
14.10.4. Recent Initiatives
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
16.1. About Us
16.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Get a Sample
Report Description
Get a Sample
Report Description